TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06579378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VSail 3D
Description: The CEREBRUM software with virtual sailing scenarios is made up of exercises of variable difficulty, designed to train different cognitive functions, in particular attention, memory, learning, cognitive estimates, working memory, executive functions, motor abilities and language. The different degrees of difficulty are designed to adapt to the user's functional diagnosis. The operator who conducts the intervention must adapt the difficulty level to the user's residual abilities, so that the exercises are neither too easy nor too complex. Each session, after an initial part of welcome, psychoeducation and orientation to the instrument, involves alternating virtual reality exercises, positive and corrective feedback, and suggestions of practical homework related to the cognitive function trained during the session that the individual should try during daily life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WEB-Health
Description: The intervention includes a series of 3 webinars focused on active ageing promotion. In particular, each webinar will regard topics related to healthy lifestyle, such as physical activity in old age, effective communication, stress management, technologies and health. Each webinar will be conducted by a mental health professional, and it will be delivered in real-time in a group (plenary).
Study: NCT04569461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg of Pembrolizumab (KEYTRUDA) will be given by IV every 3 weeks for 5 cycles, a total of 15 weeks of treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: SBRT will begin on week 7 of the study. The radiation will be given every other day in 5 fractions of 6 Gy for a total of 30 Gy of radiation exposure.
Study: NCT05715255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
Description: Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
Study: NCT04569461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation therapy
Description: Short-term ADT will last for five months. It will consist of treatment with a 1 month dose beginning on Day 0 of the study. Then it will continue with either a single 4 month dose on week 5, or 4 additional 1 month doses, depending on patient and physician preference.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy surgery will be performed between week 17 and week 20 of the study, as scheduling permits.
Study: NCT05479552

Intervention type: DIAGNOSTIC_TEST
Intervention: Syn-One Test
Description: CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
Study: NCT05715255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control comparator
Description: Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
Study: NCT05434208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic calls
Description: active telephonic follow-up program by specialist nurses until end-of-treatment (28 days)
Study: NCT06238492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: game-like computerized activities
Description: Experimental

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: game-like computerized activities
Study: NCT04981522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenously adapted problem management plus (IA-PM+)
Description: The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
Study: NCT04560920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Availability of contextual PGHD at the visit
Description: Contextual PGD will be available in a display at the visit.
Study: NCT04961996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy of Physician's Choice
Description: The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 mg will be administered orally (PO) twice a day (BID) on Days 1-28 during each 28-day cycle for 2 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
Study: NCT06585254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulator
Description: A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulator
Description: A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve
Study: NCT05472714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Investigators will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
Study: NCT05580991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection (once every 4 weeks)
Study: NCT05640999

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (EBRT +/- brachytherapy)
Description: Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
Study: NCT06259942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 1 group (underbody heater group only)
Description: Resistive heaters can be set to 38-40°C and are used together with the control unit to which they are connected. In the study, an underbody heater (MEDWARM W 300 IM 190MS branded) system measuring 1900x500x40mm was used. In this study, the underbody heater was set to 38°C for patients. Before use, a surgical drape was placed over it to prevent direct patient contact.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: İntervention 2 group (group using both underbody heater and heated iv liquid)
Description: IV fluids should be warmed to protect patients from unwanted hypothermia during surgery. One liter of saline solution given at room temperature decreases body temperature by 0.25˚C in adults. Therefore, the fluids given to the patient should be heated to 33 40˚C. In the guideline published by the Turkish Anesthesia Society, it is stated that if more than 1000 2000 mL of fluid is to be given to patients, it should be heated at 37°C (TARD, 2013). In this study, both IV fluids were heated between 37 and 39°C and given to the patient and heated with carbon fiber underbody heaters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: no active heating treatment was applied in this group
Study: NCT05640999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation
Study: NCT06267599

Intervention type: PROCEDURE
Intervention: ACAR-Style Bladder Suture
Description: In cases where dissection is not possible, the upper border of the bladder is opened transversely with a cutter, and the ureteral catheters and trigone inside the bladder are observed. The bladder invasion border is re-evaluated intravesically. The uterine arteries are held bilaterally with a sensitive clamp that does not crush the uterine arteries. Then, the uterus is incised from the upper border of the bladder without damaging the bladder and the predetermined myometrial invasion area is resected. After the placenta is removed, the cervical canal is found and marked with a number one vicryl suture. In these patients, the placental material is removed in pieces in the cervix area where the bladder is invaded. After the removal of the placenta, the cervix in the lower segment of the uterus is orientated and sutured together with the bladder, and this area is closed.
Study: NCT05278377

Intervention type: BEHAVIORAL
Intervention: Apprenti en Action program
Description: The Apprenti en Action program aims to teach students how to read and follow recipes, prepare and cook various foods using various culinary techniques, and apply food safety practices. Students are also taught the basics of healthy food, nutrition, and cooking.
Study: NCT06563102

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol/Budesonide
Description: Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Oral Inhalation. Rescue medication. Unit dose strength of 90μg albuterol per actuation.
Study: NCT06151197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Biologic: EN3835 injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT06308159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebeglogene autotemcel
Description: Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
Study: NCT06576583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engineered cartilage graft (N-TEC)
Description: Nasal chondrocytes based tissue engineered cartilage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engineered cartilage graft (N-TEC)
Description: Nasal chondrocytes based tissue engineered cartilage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Matrix Induced Chondrogenesis (AMIC)
Description: Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellofemoral Arthroplasty (PFA)
Description: Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.
Study: NCT05317468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraceptive Counseling
Description: Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraceptive Counseling
Description: Patients will receive contraceptive counseling to review all available contraceptive methods prior to their visit with a clinician.
Study: NCT04811027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist, LAG-3 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eftilagimod alpha
Description: APC activator, MHC II agonist, LAG-3 fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody
Study: NCT06527989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2000 mg
Description: antibiotic prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2000 mg
Description: antibiotic prophylaxis
Study: NCT06243978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liebria
Description: Participants will receive access to the digital health intervention liebria in addition to TAU

Intervention type: OTHER
Group type: OTHER
Intervention: information brochure on hypertension
Description: Participants will receive an information brochure on hypertension
Study: NCT04811027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: anti-PD-1 antibody
Study: NCT06651021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balcinrenone/dapagliflozin
Description: Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days.
Study: NCT05165251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET
Description: Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: amlodipine 5mg QD

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle intervention
Description: Lifestyle intervention
Study: NCT06649708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX044
Description: Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
Study: NCT05273710

Intervention type: OTHER
Group type: OTHER
Intervention: Regular toast and juice
Description: Participants consume a single test meal composed of regular whole wheat toast and apple juice, and zinc absorption is measured.

Intervention type: OTHER
Group type: OTHER
Intervention: High phytate toast and juice
Description: Participants consume a single test meal composed of high phytate whole wheat toast and apple juice, and zinc absorption is measured.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular toast and juice, with folic acid
Description: Participants consume a single test meal composed of regular whole wheat toast and apple juice, with 400 mcg folic acid; and zinc absorption is measured.
Study: NCT02804828

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Individualized mitochondrial cocktail
Description: Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 6 months for the double-blind phase
Study: NCT05452538

Intervention type: DEVICE
Intervention: Transfusion
Description: Data from patients who were transfused at the Centre Léon Bérard from the day of surgery to the 10th postoperative day will be analyzed.
Study: NCT05511285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy for Insomnia
Description: 6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online, in addition to usual care.
Study: NCT05938153

Intervention type: OTHER
Intervention: observational physical tests
Description: Geriatric Locomotive Function Scale:~This scale consists of a questionnaire of 25 items that can be easily understood by the elderly and each item is graded between 0 and 4 points. The total score is the result of the sum of all items ranging from 0 to 100; the higher the score, the higher the physical impairment of the elderly, with a score of 16 being the cut-off point for locomotive syndrome. The GLFS-25 includes 4 questions about pain, 16 questions about activities of daily living, 3 questions about social performance and 2 questions about mental health status to assess geriatric individuals. Turkish validity and reliability of the questionnaire was conducted by Sadikoglu.
Study: NCT06365827

Intervention type: OTHER
Intervention: observational study
Description: no intervention of interest
Study: NCT04741503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Cancer Screening Decision Support Tool
Description: -Provides a description of screening mammography, current screening recommendations, benefits and downsides, narratives, and questions for the participant's physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: National Cancer Institute Breast Cancer Screening PDQ
Description: -Provides current information about breast cancer screening and is meant to inform and help patients
Study: NCT04849026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril 100 mg (Clozapine)
Description: 2 Doses/Day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozaril 100 mg (Clozapine)
Description: 2 Doses/Day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WID-CLZ18
Description: 2 Doses/Day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WID-CLZ18
Description: 2 Doses/Day for 10 days
Study: NCT05684250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback training
Description: For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback training
Description: For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback training
Description: For the auditory biofeedback training, subjects are provided with two tones while fixating a target, one tone related to their accommodative response and the second to the target distance. Their task is to match these tones.
Study: NCT05507554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid Analgesic
Description: Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid
Description: Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Diclofenac Sodium 50 mg) will be given to the patients on discharge. For Pain control oral Diclofenac Sodium 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.